Aurobindo Pharma Stock

Aurobindo Pharma EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Aurobindo Pharma (AUROPHARMA.NS) as of Aug 21, 2026 is 52.47. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -65.68 — a change of -179.89% (higher).

EV/FCF

52.47

YoY

-179.89%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Aurobindo Pharma is 2026 52.47 . EV/FCF (Enterprise Value to Free Cash Flow) of Aurobindo Pharma was 2025 -65.68 . It decreases by -179.89% higher compared to the previous year.
Access this data via the Eulerpool API

Aurobindo Pharma Stock analysis

What does Aurobindo Pharma do? Aurobindo Pharma Ltd is a global pharmaceutical company based in India. It was founded in 1986 by P.V. Ramprasad Reddy, K. Nityananda Reddy, and Kambhampati Hari Babu. It has become one of the leading companies in the industry over the past 35 years. The company's business model is based on the production and distribution of generics, active pharmaceutical ingredients, and biosimilars. It operates in several divisions, covering a wide range of products. Aurobindo Pharma's main division is the manufacturing of generics, including both simple generics and complex products like biosimilars. The company also produces a variety of pharmaceutical ingredients used in industries such as pharmacy, cosmetics, and food. In addition, Aurobindo is involved in the production of biosimilars, which are biological drugs that have similar properties to existing biological products. These products have the potential to improve access to life-saving medications and generate significant cost savings. Aurobindo also manufactures products for the veterinary medicine industry, including antibiotics, antiparasitics, and vitamins. The company has also established a strong presence in the American market in recent years through acquisitions and offers a wide range of products. It has also expanded its presence in Europe, Asia, and Africa. In 2020, Aurobindo Pharma played a significant role in combating the COVID-19 pandemic by introducing several medications that can be used to treat the virus, such as hydroxychloroquine and azithromycin for mild to moderate cases. The company has earned a reputation as a leader in the generics and active pharmaceutical ingredient markets and aims to provide high-quality medications at affordable prices, making a positive contribution to global health improvement. Aurobindo Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aurobindo Pharma stock

EV/FCF (Enterprise Value to Free Cash Flow) of Aurobindo Pharma is 52.47 in 2026.

EV/FCF (Enterprise Value to Free Cash Flow) of Aurobindo Pharma changed from -65.68 to 52.47, representing a -179.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Aurobindo Pharma since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Aurobindo Pharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Aurobindo Pharma

All Key Metrics — Aurobindo Pharma